Advanced Filters
noise

heart-failure Clinical Trials

A listing of heart-failure medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 840 clinical trials
C Cassandra J Demastus

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism \[Empagliflozin (Empa)\], with and without additional supplements that increase perfusion and fatty acid oxidation \[Potassium Nitrate (KNO3)\], improve submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in participants with Heart Failure …

18 years of age All Phase 2
A Alexandria Berns, PharmD

Transitions of Care Clinic (TOCC)

The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multiple comorbidities. This project proposes to expand …

18 - 90 years of age All Phase N/A
P Prof Al-Mohammad

The Use of Advanced Imaging in HFpEF

Heart failure with preserved ejection fraction (HFpEF) causes symptoms of breathlessness and leg swelling. It is associated with significant number of hospital admissions and could lead to the patient's death. In HFpEF, the pumping function of the heart is normal but the heart is too stiff to fill properly. The …

18 years of age All Phase N/A
D David W Wray, PhD

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).

18 years of age All Phase 1
P Pooja Sethi, MD

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Our local IRB approved clinical studies seeking proof of principle for the hypothesis that SFN can be safely administered to humans at doses sufficient to protect age-associated cardiac dysfunctions. Beneficial effects of SFN-therapy will be assessed by Pre- and post-intervention echocardiography, and exercise endurance at 0 and 24 weeks. Peripheral …

60 - 80 years of age All Phase 1/2
G General Internal Medicine

Training Medical Residents in the Use of the Venous Excess UltraSound (VExUS) Score for Bedside Volume Assessment.

This randomized controlled trial evaluates the effectiveness of two training approaches (in-person versus remote) for teaching medical residents to apply the Venous Excess Ultrasound (VExUS) score for bedside volume assessment in patients with acute heart failure. Resident performance will be compared to that of expert physicians certified in abdominal and …

years of age All Phase N/A
K Klaus Witte

Optimising Pacing for Contractility 2

The investigators have demonstrated that they can reliably identify an optimum heart rate range for contractility of the left ventricle in patients with chronic heart failure (CHF). They have also demonstrated in an acute cross-over and a small parallel group feasibility study that keeping the heart rate in this range …

18 years of age All Phase 2/3

Comparison of Cardiac Index and Stroke-volume-index Measured by Pulmonary Artery Catheter, FloTrac® and Argos® in Cardiac Surgery Patients.

A comparison of cardiac performance determined by stroke-volume-index measured by different mechanisms in patients during and after cardiac surgery: Pulmonary artery catheter Flo Trac Argos Monitor Investigations will be done in theater and on ICU in ventilated and spontaneously breathing patients.

18 years of age All Phase N/A
J Jessica N Alcala, RN

Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contributor to DOE and exercise intolerance …

55 - 90 years of age All Phase N/A
Y Yuejuan Qin, PhD

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.

18 - 80 years of age All Phase 0

Simplify language using AI